| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Bergmann, U. C., et al.
(författare)
-
Beta-decay properties of the neutron-rich Kr94-99 and Xe142-147 isotopes
- 2003
-
Ingår i: Nuclear Physics A. - 0375-9474. ; 714:1-2, s. 21-43
-
Tidskriftsartikel (refereegranskat)abstract
- Beta-decay half-lives and delayed-neutron emission probabilities of the neutron-rich noble-gas isotopes Kr94-99 and Xe142-147 have been measured at the PSB-ISOLDE facility at CERN. The results are compared to QRPA shell-model predictions and are used in dynamic calculations of r-process abundances of Kr and Xe isotopes. (C) 2002 Elsevier Science B.V. All rights reserved.
|
|
| 5. |
|
|
| 6. |
- du Rietz, Rickard, et al.
(författare)
-
Effective Charges in the fp Shell
- 2004
-
Ingår i: Physical Review Letters. - 1079-7114. ; 93:22
-
Tidskriftsartikel (refereegranskat)abstract
- Following the heavy-ion fusion-evaporation reaction S-32+Mg-24 at 95 MeV beam energy the lifetimes of analogue states in the T-z=+/-1/2 A=51 mirror nuclei Fe-51 and Mn-51 have been measured using the Cologne plunger device coupled to the GASP gamma-ray spectrometer. The deduced B(E2;27/2(-)-->23/2(-)) values afford a unique opportunity to probe isoscalar and isovector polarization charges and to derive effective proton and neutron charges, epsilon(p) and epsilon(n), in the fp shell. A comparison between the experimental results and several different large-scale shell-model calculations yields epsilon(p)similar to1.15e and epsilon(n)similar to0.80e.
|
|
| 7. |
- Lemme, Max C., 1970-, et al.
(författare)
-
Triple-gate metal-oxide-semiconductor field effect transistors fabricated with interference lithography
- 2004
-
Ingår i: Nanotechnology. - : IOP Publishing. - 0957-4484 .- 1361-6528. ; 15:4, s. S208-S210
-
Tidskriftsartikel (refereegranskat)abstract
- In this work, n-type triple-crate metal-oxide-semiconductor field effect transistors (MOSFETs) are presented, where laser interference lithography (LIL) is integrated into a silicon-on-insulator (SOI) CMOS process to provide for the critical definition of the transistor channels. A mix and match process of optical contact lithography and LIL is developed to achieve device relevant structures. The triple-gate MOSFETs are electrically characterized to demonstrate the feasibility of this low cost fabrication process.
|
|
| 8. |
- Narod, SA, et al.
(författare)
-
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
- 2002
-
Ingår i: Journal of the National Cancer Institute. - : Oxford University Press (OUP). - 1460-2105. ; 94:23, s. 1773-1779
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Oral contraceptive use has been associated with an increase in the risk of breast cancer in young women. We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2. Methods: We performed a matched case-control study on 1311 pairs of women with known deleterious BRCA1 and/or BRCA2 mutations recruited from 52 centers in 11 countries. Women who had been diagnosed with breast cancer were matched to control subjects by year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of ovarian cancer. All study subjects completed a questionnaire about oral contraceptive use. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived by conditional logistic regression. All statistical tests were two-sided. Results: Among BRCA2 mutation carriers, ever use of oral contraceptives was not associated with an increased risk of breast cancer (OR = 0.94, 95% CI = 0.72 to 1.24). For BRCAI mutation carriers, ever use of oral contraceptives was associated With a modestly increased risk of breast cancer (OR = 1.20, 95 % CI = 1.02 to 1.40). However, compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR = 1.33, 95% CI = 1.11 to 1.60), as did those who used oral contraceptives before age 30 (OR = 1.29, 95% CI = 1.09 to 1.52), those who were diagnosed with breast cancer before age 40 (OR = 1.38, 95% CI = 1.11 to 1.72), and those who first used oral contraceptives before 1975 (OR = 1.42, 95 % CI = 1.17 to 1.75). Conclusions: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.
|
|
| 9. |
|
|
| 10. |
|
|
